CLOs on the Move

Vein360

www.vein360.com

 
Vein 360 Specializes in reprocessing Closurefast Ablation Catheters. The Vein 360 team is dedicated to providing cost effective reprocessing services.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.vein360.com
  • 4460, Lake Forest Drive
    Blue Ash, OH USA 45242
  • Phone: 513.554.1300

Executives

Name Title Contact Details

Similar Companies

Impax Laboratories

Impax Laboratories is a technology-based specialty pharmaceutical company utilizing our core competency in drug delivery and formulation expertise. We have a balanced business model consisting of a successful generic business targeting high-value solid oral and alternative dosage form Abbreviated New Drug Applications (ANDA), and a branded business currently focused on internally developing Central Nervous System (CNS) products where we can deliver meaningful patient benefits and develop strong intellectual property positions.

Validation Professionals

Validation Professionals, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Cornerstone Family Healthcare

Cornerstone Family Healthcare is a comprehensive Hudson Valley medical care provider, offering urgent care, preventative care, womens health, pediatrics and more.

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.

Venture Technology Group

Venture Technology Group is a Farmington Hls, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.